Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer

Phase 2

Conditions: Recurrent Head and Neck Cancer

Interventions: Radiation: Radiation
Device: Hyperthermia; Thermotron RF-8
Drug: Cisplatin
Drug: Taxotere

First Posted Date: 2015-10-05

Last Posted Date: 2020-07-28

Lead Sponsor: Shin Kong Wu Ho-Su Memorial Hospital

Target Recruit Count: 45

Registration Number: NCT02567383

Locations: 🇨🇳
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Carcinoma of Unknown Primary
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Head and Neck Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

Interventions: Drug: Berzosertib
Drug: Cisplatin
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2015-10-05

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT02567422

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 16 locations

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Bladder Urothelial Carcinoma AJCC v7
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma

Interventions: Drug: Berzosertib
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride

First Posted Date: 2015-10-05

Last Posted Date: 2024-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT02567409

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 36 locations

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Cisplatin

First Posted Date: 2015-09-29

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 316

Registration Number: NCT02563054

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Phase 2

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: Gemcitabine
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2015-09-25

Last Posted Date: 2018-11-28

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 3

Registration Number: NCT02560038

Locations: 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Phase 2

Active, not recruiting

Conditions: Anal Basaloid Carcinoma
Stage IV Anal Canal Cancer
Recurrent Anal Canal Carcinoma
Anal Squamous Cell Carcinoma
Metastatic Anal Canal Carcinoma
Stage IIIB Anal Canal Cancer
Anal Canal Cloacogenic Carcinoma

Interventions: Drug: Capecitabine
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Fluorouracil
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2015-09-25

Last Posted Date: 2023-06-22

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 91

Registration Number: NCT02560298

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Prexasertib
Drug: Cisplatin
Drug: Cetuximab
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2015-09-21

Last Posted Date: 2019-02-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT02555644

Locations: 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 1 locations

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Biological: Cetuximab
Biological: MEDI4736
Biological: Tremelimumab
Biological: MEDI4736+Tremelimumab
Drug: 5-fluorouracil (5FU)
Drug: Cisplatin
Drug: Carboplatin